Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Sanofi SA (SNY) vs United Microelectronics Corp (UMC) Price & Performance

United Microelectronics CorpTrade

Price performance (Past 24H)

Key statistics

Sanofi SA vs United Microelectronics Corp — how do they compare? Sanofi SA trades at $43.61 (market cap $104.30B), while United Microelectronics Corp trades at $19.51 (market cap $47.81B). The key difference: Sanofi SA is far larger — about 2.2× United Microelectronics Corp's market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.

SNYUMC
Market Cap
$104.30B$47.81B
Sector
HealthTechnology
52-Week High
$52.34$28.02
52-Week Low
$41.33$6.58
Enterprise Value
$124.19B$44.93B
Dividend Yield
5.55%2.12%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Sanofi SA

SNY trades at $43.54, up 0.14% today, with a neutral technical signal and bullish moving averages. Recent Q2 2026 earnings beat expectations, with EPS of $1.21 versus $1.10 expected, driven by strong Dupixent sales. The company raised its 2026 outlook, projecting ~10% sales growth. Financial health is solid with a P/E of 23.27 and robust operating cash flow of $10.75B in 2025, though net cash flow was minimal at $49M.

Outlook is cautiously optimistic with growth catalysts from Dupixent and new drug approvals, but risks include pipeline setbacks and competitive pressures. Analysts are mixed, with 44% buy ratings, highlighting potential upside to fair value estimates around $57, while debt levels and regulatory scrutiny pose challenges for sustained shareholder value.

United Microelectronics Corp

UMC trades at $19.40, up 3.25% with a neutral technical signal. The company reported strong Q2 2026 earnings, beating estimates with $0.54 EPS, and announced fab expansions in Singapore and Taiwan to meet AI demand. Revenue growth is projected to rise to $250.7 billion in 2026, with net income margin improving to 32.75%. Cash flow turned positive in 2025 at $5.66 billion, supporting strategic investments.

Outlook is positive due to AI-driven demand and operational execution, but risks include competitive pressures and capital expenditure volatility. Analysts show mixed sentiment with 26.7% buy ratings, highlighting cautious optimism amid expansion plans.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Sanofi SA

Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Read more on SNY

About United Microelectronics Corp

Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.

Read more on UMC